Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
9.24
+0.05 (0.54%)
At close: Aug 10, 2026, 4:00 PM EDT
9.20
-0.04 (-0.43%)
After-hours: Aug 10, 2026, 4:56 PM EDT
Ocular Therapeutix Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Ocular Therapeutix stock has a consensus rating of "Strong Buy" and an average price target of $27.09. The average 1-year stock price forecast is 193.18% higher than the current stock price, while the lowest is $18 (+94.81%) and the highest is $34 (+267.97%).
Price Target: $27.09 (+193.18%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ocular Therapeutix stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Reiterates $27 | Buy | Reiterates | $27 | +192.21% | Aug 7, 2026 |
| Clear Street | Clear Street | Buy Maintains $28 | Buy | Maintains | $28 | +203.03% | Aug 4, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +170.56% | Aug 4, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $20 | Buy | Maintains | $20 | +116.45% | Aug 4, 2026 |
| Needham | Needham | Buy Maintains $18 | Buy | Maintains | $18 | +94.81% | Aug 3, 2026 |
Financial Forecast
Revenue This Year
52.61M
from 51.95M
Increased by 1.27%
Revenue Next Year
102.50M
from 52.61M
Increased by 94.84%
EPS This Year
-1.39
from -1.42
EPS Next Year
-1.47
from -1.39
EPS and Forward PE are based on non-GAAP adjusted numbers.